Oral Prednisolone to Prevent Esophageal Stricture After RFA for Long-segment Esophageal Neoplasia

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Endoscopic radiofrequency ablation (RFA) has shown good efficacy and safety in eradicating flat-type early esophageal squamous cell neoplasia (ESCN). However, post-RFA stricture is still a major concern, especially when treating long-segment early ESCNs. The aim of this study was to investigate the efficacy and safety of oral prednisolone to prevent post-RFA stricture.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: E-DA Hospital
• Treatments: Prednisolone

Criteria

Inclusion Criteria:

• Histology from endoscopic biopsies showed squamous intraepithelial neoplasia without stromal invasion;

• No lymph node metastasis on endoscopic ultrasound or computed tomography;

• Magnifying endoscopy showed the intraepithelial papillary capillary loop as type B1 pattern, according to the classification of the microvascular architecture of superficial esophageal carcinoma.

Exclusion Criteria:

• A prior history of endoscopic resection, radiation therapy or esophagectomy for esophageal cancer;

• A stricture that prevented the passage of a therapeutic endoscope;

• Uncontrolled coagulopathy;

• Poorly controlled diabetes mellitus.